FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108767555> ?p ?o ?g. }

• W2108767555 endingPage "455" @default.
• W2108767555 startingPage "449" @default.
• W2108767555 abstract "Patients with multiple myeloma (MM) achieving high-quality responses, defined as a complete response (CR) and a very good partial response (VGPR) after transplant, benefit from high-dose therapy followed by autologous stem cell transplantation (ASCT). Induction pre-transplantation treatment with vincristine, doxorubicin and dexamethasone (VAD) is currently being replaced by new targeted agents with high anti-myeloma activity. The use of these novel agents may increase the CR + VGPR rate before ASCT, which may improve post-transplantation responses and survival.We performed a retrospective analysis of 69 patients with MM who received bortezomib-containing regimens (n = 30) or VAD (n = 39) before collection of peripheral blood stem cells and ASCT.Objective response rate (at least a partial response) prior to ASCT was documented in 27 (90%) of 30 and 31 (81.6%) of evaluable 38 patients with bortezomib-containing regimens and VAD, respectively. The difference between the two groups was not significant (P = 0.494). However, the high-quality response rate with VGPR or more in the bortezomib group was significantly higher compared with the VAD group (66.7% vs. 34.2%, respectively, P = 0.006). The superiority of bortezomib-containing regimens in the high-quality response rate remained significant for only the newly diagnosed patients (n = 16, P = 0.008). The engraftment data as well as stem cell harvesting were comparable between the two groups. The major bortezomib-related toxicities were thrombocytopenias and peripheral neuropathies; toxicities of VAD were hematologic and infectious. After ASCT, the difference between the two groups did not reach the level of statistical significance with respect to progression-free survival and overall survival (P = 0.498 and 0.835, respectively).The results of this retrospective comparison of bortezomib-containing regimens with the VAD as induction treatment prior to ASCT for MM provided a demonstration of the superiority of bortezomib therapy in terms of achieving a high-quality response. However, survivals following ASCT did not differ according to the induction regimens." @default.
• W2108767555 created "2016-06-24" @default.
• W2108767555 creator A5009032518 @default.
• W2108767555 creator A5021499196 @default.
• W2108767555 creator A5036020306 @default.
• W2108767555 creator A5043910009 @default.
• W2108767555 creator A5050292329 @default.
• W2108767555 creator A5057482418 @default.
• W2108767555 creator A5061707434 @default.
• W2108767555 creator A5076088179 @default.
• W2108767555 creator A5086500437 @default.
• W2108767555 date "2009-06-01" @default.
• W2108767555 modified "2023-09-24" @default.
• W2108767555 title "Retrospective Comparison of Bortezomib-containing Regimens with Vincristine-Doxorubicin-Dexamethasone (VAD) as Induction Treatment Prior to Autologous Stem Cell Transplantation for Multiple Myeloma" @default.
• W2108767555 cites W1978377409 @default.
• W2108767555 cites W1983192779 @default.
• W2108767555 cites W1987619563 @default.
• W2108767555 cites W1992935261 @default.
• W2108767555 cites W2013902170 @default.
• W2108767555 cites W2022248147 @default.
• W2108767555 cites W2025253157 @default.
• W2108767555 cites W2044436186 @default.
• W2108767555 cites W2067145347 @default.
• W2108767555 cites W2078115159 @default.
• W2108767555 cites W2079067522 @default.
• W2108767555 cites W2083107653 @default.
• W2108767555 cites W2102591890 @default.
• W2108767555 cites W2107154392 @default.
• W2108767555 cites W2108235071 @default.
• W2108767555 cites W2124560610 @default.
• W2108767555 cites W2146502962 @default.
• W2108767555 cites W2146607984 @default.
• W2108767555 cites W2157256629 @default.
• W2108767555 cites W3145716452 @default.
• W2108767555 cites W4236730981 @default.
• W2108767555 cites W4237181574 @default.
• W2108767555 doi "https://doi.org/10.1093/jjco/hyp046" @default.
• W2108767555 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19487425" @default.
• W2108767555 hasPublicationYear "2009" @default.
• W2108767555 type Work @default.
• W2108767555 sameAs 2108767555 @default.
• W2108767555 citedByCount "6" @default.
• W2108767555 countsByYear W21087675552013 @default.
• W2108767555 countsByYear W21087675552015 @default.
• W2108767555 countsByYear W21087675552017 @default.
• W2108767555 countsByYear W21087675552020 @default.
• W2108767555 crossrefType "journal-article" @default.
• W2108767555 hasAuthorship W2108767555A5009032518 @default.
• W2108767555 hasAuthorship W2108767555A5021499196 @default.
• W2108767555 hasAuthorship W2108767555A5036020306 @default.
• W2108767555 hasAuthorship W2108767555A5043910009 @default.
• W2108767555 hasAuthorship W2108767555A5050292329 @default.
• W2108767555 hasAuthorship W2108767555A5057482418 @default.
• W2108767555 hasAuthorship W2108767555A5061707434 @default.
• W2108767555 hasAuthorship W2108767555A5076088179 @default.
• W2108767555 hasAuthorship W2108767555A5086500437 @default.
• W2108767555 hasBestOaLocation W21087675551 @default.
• W2108767555 hasConcept C126322002 @default.
• W2108767555 hasConcept C126894567 @default.
• W2108767555 hasConcept C141071460 @default.
• W2108767555 hasConcept C143998085 @default.
• W2108767555 hasConcept C2776364478 @default.
• W2108767555 hasConcept C2776694085 @default.
• W2108767555 hasConcept C2776755627 @default.
• W2108767555 hasConcept C2777478702 @default.
• W2108767555 hasConcept C2779050716 @default.
• W2108767555 hasConcept C2779429289 @default.
• W2108767555 hasConcept C2780401358 @default.
• W2108767555 hasConcept C2911091166 @default.
• W2108767555 hasConcept C71924100 @default.
• W2108767555 hasConcept C90924648 @default.
• W2108767555 hasConceptScore W2108767555C126322002 @default.
• W2108767555 hasConceptScore W2108767555C126894567 @default.
• W2108767555 hasConceptScore W2108767555C141071460 @default.
• W2108767555 hasConceptScore W2108767555C143998085 @default.
• W2108767555 hasConceptScore W2108767555C2776364478 @default.
• W2108767555 hasConceptScore W2108767555C2776694085 @default.
• W2108767555 hasConceptScore W2108767555C2776755627 @default.
• W2108767555 hasConceptScore W2108767555C2777478702 @default.
• W2108767555 hasConceptScore W2108767555C2779050716 @default.
• W2108767555 hasConceptScore W2108767555C2779429289 @default.
• W2108767555 hasConceptScore W2108767555C2780401358 @default.
• W2108767555 hasConceptScore W2108767555C2911091166 @default.
• W2108767555 hasConceptScore W2108767555C71924100 @default.
• W2108767555 hasConceptScore W2108767555C90924648 @default.
• W2108767555 hasIssue "7" @default.
• W2108767555 hasLocation W21087675551 @default.
• W2108767555 hasLocation W21087675552 @default.
• W2108767555 hasOpenAccess W2108767555 @default.
• W2108767555 hasPrimaryLocation W21087675551 @default.
• W2108767555 hasRelatedWork W1963774766 @default.
• W2108767555 hasRelatedWork W2003527606 @default.
• W2108767555 hasRelatedWork W2056236957 @default.
• W2108767555 hasRelatedWork W2067463209 @default.
• W2108767555 hasRelatedWork W2089651698 @default.
• W2108767555 hasRelatedWork W2136773918 @default.
• W2108767555 hasRelatedWork W2160188479 @default.
• W2108767555 hasRelatedWork W2427804748 @default.

• next